Monocytes and neutrophils as 'bad guys' for the outcome of interleukin-2 with and without histamine in metastatic renal cell carcinoma - Results from a randomised phase II trial

British Journal of Cancer

Volumn 94, Issue 2, 2006, Pages 218-226

  Donskov, F ^a,b   Hokland, M ^b   Marcussen, N ^a   Torp Madsen, H H ^a   Von Der Maase, H ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

Histamine dihydrochloride, oxidative stress; Interleukin 2; Renal cell carcinoma

Indexed keywords

HISTAMINE; RECOMBINANT INTERLEUKIN 2;

ARTICLE; BLOOD SAMPLING; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COURSE EVALUATION; DISEASE COURSE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; DRUG POTENCY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY METASTASIS; LEUKOCYTE COUNT; MACROPHAGE; MONOCYTE; MONOTHERAPY; NATURAL KILLER T CELL; NEUTROPHIL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR BIOPSY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE II; FEMALE; HISTAMINE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-2; KIDNEY NEOPLASMS; KILLER CELLS, NATURAL; MALE; MONOCYTES; NEOPLASM METASTASIS; NEUTROPHILS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 31444436326     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602937     Document Type: Article

References (49)

1. Agarwala SS, Glaspy J, O'Day SJ, Mitchell M, Gutheil J, Whitman E, Gonzalez R, Hersh E, Feun L, Belt R, Meyskens F, Hellstrand K, Wood D, Kirkwood JM, Gehlsen KR, Naredi P (2002) Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol 20: 125-133
2. Agarwala SS, Hellstrand K, Gehlsen K, Naredi P (2004) Immunotherapy with histamine and interleukin 2 in malignant melanoma with liver metastasis. Cancer Immunol Immunother 53: 840-841
3. Asea A, Hermodsson S, Hellstrand K (1996) Histaminergic regulation of natural killer cell-mediated clearance of tumour cells in mice. Scand J Immunol 43: 9-15
4. Atzpodien J, Royston P, Wandert T, Reitz M (2003) Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer 88: 348-353
5. Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357: 539-545
6. Betten A, Dahlgren C, Hermodsson S, Hellstrand K (2003) Histamine inhibits neutrophil NADPH oxidase activity triggered by the lipoxin A4 receptor-specific peptide agonist Trp-Lys-Tyr-Met-Val-Met. Scand J Immunol 58: 321-326
7. Brune M, Hellstrand K (1996) Remission maintenance therapy with histamine and interleukin-2 in acute myelogenous leukaemia. Br J Haematol 92: 620-626
8. Chen JJ, Lin YC, Yao PL, Yuan A, Chen HY, Shun CT, Tsai MF, Chen CH, Yang PC (2005) Tumor-associated macrophages: the double-edged sword in cancer progression. J Clin Oncol 23: 953-964
9. Coussens LM, Werb Z (2001) Inflammatory cells and cancer: think different!. J Exp Med 193: F23-F26
10. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420: 860-867
11. Donskov F, Bennedsgaard KM, Hokland M, Marcussen N, Fisker R, Madsen HH, Fode K, von der Maase H (2004a) Leukocyte orchestration in blood and tumour tissue following interleukin-2 based immunotherapy in metastatic renal cell carcinoma. Cancer Immunol Immunother 53: 729-739
12. Donskov F, Bennedsgaard KM, von der Maase H, Marcussen N, Fisker R, Jensen JJ, Naredi P, Hokland M (2002a) Intratumoural and peripheral blood lymphocyte subsets in patients with metastatic renal cell carcinoma undergoing interleukin-2 based immunotherapy: association to objective response and survival. Br J Cancer 87: 194-201
13. Donskov F, Middleton M, Fode K, Meldgaard P, Mansoor W, Lawrance J, Thatcher N, Nellemann H, von der Maase H (2005) Two randomised phase II trials of subcutaneous interleukin-2 and histamine dihydrochloride in patients with metastatic renal cell carcinoma. Br J Cancer 93: 757-762
14. Donskov F, von der Maase H, Henriksson R, Stierner U, Wersall P, Nellemann H, Hellstrand K, Engman K, Naredi P (2002b) Outpatient treatment with subcutaneous histamine dihydrochloride in combination with interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma: results of an open single-armed multicentre phase II study. Ann Oncol 13: 441-449
15. Donskov F, von der Maase H, Marcussen N, Hamilton-Dutoit S, Madsen HH, Jensen JJ, Hokland M (2004b) Fas ligand expression in metastatic renal cell carcinoma during interleukin-2 based immunotherapy: no in vivo effect of Fas ligand tumor counterattack. Clin Cancer Res 10: 7911-7916
16. Finke JH, Zea AH, Stanley J, Longo DL, Mizoguchi H, Tubbs RR, Wiltrout RH, O'Shea JJ, Kudoh S, Klein E (1993) Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res 53: 5613-5616
17. Gundersen HJ, Bendtsen TF, Korbo L, Marcussen N, Moller A, Nielsen K, Nyengaard JR, Pakkenberg B, Sorensen FB, Vesterby A (1988) Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. APMIS 96: 379-394
18. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57-70
19. Hansson M, Asea A, Ersson U, Hermodsson S, Hellstrand K (1996) Induction of apoptosis in NK cells by monocyte-derived reactive oxygen metabolites. J Immunol 156: 42-47
20. Hansson M, Hermodsson S, Brune M, Mellqvist UH, Naredi P, Betten A, Gehlsen KR, Hellstrand K (1999) Histamine protects T cells and natural killer cells against oxidative stress. J Interferon Cytokine Res 19: 1135-1144
21. Hellstrand K (2002) Histamine in cancer immunotherapy: a preclinical background. Semin Oncol 29: 35-40
22. Hellstrand K, Asea A, Dahlgren C, Hermodsson S (1994) Histaminergic regulation of NK cells. Role of monocyte-derived reactive oxygen metabolites. J Immunol 153: 4940-4947
23. Hellstrand K, Asea A, Hermodsson S (1990) Role of histamine in natural killer cell-mediated resistance against tumor cells. J Immunol 145: 4365-4370
24. Hellstrand K, Hermodsson S (1986) Histamine H2-receptor-mediated regulation of human natural killer cell activity. J Immunol 137: 656-660
25. Hellstrand K, Hermodsson S (1990) Synergistic activation of human natural killer cell cytotoxicity by histamine and interleukin-2. Int Arch Allergy Appl Immunol 92: 379-389
26. Herberman RB (2002) Cancer immunotherapy with natural killer cells. Semin Oncol 29: 27-30
27. Hermann GG, Geertsen PF, von der Maase H, Zeuthen J (1991) Interleukin-2 dose, blood monocyte and CD25+ lymphocyte counts as predictors of clinical response to interleukin-2 therapy in patients with renal cell carcinoma. Cancer Immunol Immunother 34: 111-114
28. Kono K, Salazar-Onfray F, Petersson M, Hansson J, Masucci G, Wasserman K, Nakazawa T, Anderson P, Kiessling R (1996) Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell- and natural killer cell-mediated cytotoxicity. Eur J Immunol 26: 1308-1313
29. Lin EY, Pollard JW (2004) Role of infiltrated leucocytes in tumour growth and spread. Br J Cancer 90: 2053-2058
30. Lopez HE, Kirchner H, Atzpodien J (1996) Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol 155: 19-25
31. Lurie Y, Nevens F, Aprosina ZG, Fedorova TA, Kalinin AV, Klimova EA, Ilan Y, Maevskaya MV, Warnes TW, Yuschuk ND, Hellstrand K, Gehlsen KR (2002) A multicentre, randomized study to evaluate the safety and efficacy of histamine dihydrochloride and interferon-alpha-2b for the treatment of chronic hepatitis C. J Viral Hepat 9: 346-353
32. Malmberg KJ (2004) Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape? Cancer Immunol Immunother 53: 879-892
33. McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff MS, Tretter CP, Urba WJ, Smith JW, Margolin KA, Mier JW, Gollob JA, Dutcher JP, Atkins MB (2005) Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23: 133-141
34. Mellqvist UH, Wallhult E, Brune M, Jacobsson S, Hellstrand K (1999) Histamine dihydrochloride, interleukin-2 and interferon-alfa in multiple myeloma. Int J Immunother 15: 125-130
35. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207-214
36. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17: 2530-2540
37. Murdoch C, Giannoudis A, Lewis CE (2004) Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 104: 2224-2234
38. Negrier S, Escudier B, Gomez F, Douillard JY, Ravaud A, Chevreau C, Buclon M, Perol D, Lasset C (2002) Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d'Immunotherapie. Ann Oncol 13: 1460-1468
39. Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T, Tursz T (1998) Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 338: 1272-1278
40. O'Byrne KJ, Dalgleish AG (2001) Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer 85: 473-483
41. Pollard JW (2004) Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4: 71-78
42. Rosenberg SA (2001) Progress in human tumour immunology and immunotherapy. Nature 411: 380-384
43. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313: 1485-1492
44. Samlowski WE, Petersen R, Cuzzocrea S, Macarthur H, Burton D, McGregor JR, Salvemini D (2003) A nonpeptidyl mimic of superoxide dismutase, M40403, inhibits dose-limiting hypotension associated with interleukin-2 and increases its antitumor effects. Nat Med 9: 750-755
45. Schmidt H, Larsen S, Bastholt L, Fode K, Rytter C, von der Maase H (2002) A phase II study of outpatient subcutaneous histamine dihydrochloride, interleukin-2 and interferon-alpha in patients with metastatic melanoma. Ann Oncol 13: 1919-1924
46. Seaman WE, Gindhart TD, Blackman MA, Dalal B, Talal N, Werb Z (1982) Suppression of natural killing in vitro by monocytes and polymorphonuclear leukocytes: requirement for reactive metabolites of oxygen. J Clin Invest 69: 876-888
47. Tartour E, Latour S, Mathiot C, Thiounn N, Mosseri V, Joyeux I, D'Enghien CD, Lee R, Debre B, Fridman WH (1995) Variable expression of CD3-zeta chain in tumor-infiltrating lymphocytes (TIL) derived from renal-cell carcinoma: relationship with TIL phenotype and function. Int J Cancer 63: 205-212
48. Vakkila J, Lotze MT (2004) Inflammation and necrosis promote tumour growth. Nat Rev Immunol 4: 641-648
49. Wyckoff J, Wang W, Lin EY, Wang Y, Pixley F, Stanley ER, Graf T, Pollard JW, Segall J, Condeelis J (2004) A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res 64: 7022-7029